Unlocking the brain to biologics

 

About us

 

Key2Brain is a Swedish biotechnology company committed to developing a novel and efficacious brain targeting platform technology.

With unique molecules and preclinical expertise, Key2Brain provides solutions for enhanced brain uptake of biologics and diagnostics. Key2Brain is a partner for preclinical development of therapeutics treating the central nervous system (CNS).

Our goal is to improve treatment and diagnostic options for diseases of the CNS.

The technology

Key2Brain is developing a proprietary technology to enable brain access to biopharmaceuticals. Please contact us to learn more.

 

Our expertise

With extensive experience in drug discovery and development of biologics, our team will facilitate a preclinical way towards clinic, using our technology.

 

Collaboration and Partnership

Key2Brain is a semi-virtual company. Our business model relies on collaboration and partnership with academia and industry. Please contact us to know more.

 

The Team

Operations

Chao Su, PhD
Principal Scientist

Dominik Possner, PhD
Principal Scientist

Magnus Berglund, PhD
Chief Technical Officer

Elisabet Sjöström, PhD
Founder, CEO

Senior Consultant
Corporate Development and Strategy

Tiffany Dallas, MSc
Scientist

Scientific Advisory Board

Anna Sandegren, PhD

Tobias Cornvik, PhD

Stephen James, PhD

Stefan S Gelius, PhD


Board of Directors

Board Member, Andreas Gretander

Board Member, Stephen James

Board Member, Nina Fleck

Vice chair,
Kristina Magnusson Borg

Chair,
Elisabet O Sjöström

Photo: Rebecca Faresjö, Magnus Berglund

Contact


Email
info@key2brain.se

Visit us
Karolinska Institute Campus, Innomedicum, A Working Lab (AWL)
Nanna Svartz Väg 4, Solna

News

  • Key2Brain awarded VINNOVA funding

    May 2023 -

    Key2Brain was in May 2023 awarded “Innovative start-ups grant step 2” from VINNOVA, Sweden’s Innovation Agency

  • Team Expansion

    June 2023 -

    Key2Brain has expanded the team with core competence within Business Development and Science

  • Funding: VINNOVA Acceleration for deeptech companies

    November 2023 -

    Once again Key2Brain is supported by VINNOVA to accelerate our technology development

    SEK 1 m funded for the first stage, with a possibility to get up to SEK 4 m in total over 3 years.